Volume 12, Issue 2 (10-2024)
Jorjani Biomed J 2024, 12(2): 10-13 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Omidi F, Fozouni L, Nikyar A, Mahmood Janlou M A. Sensitivity profile of carbapenem-resistant uropathogenic bacterial isolates to Cefiderocol. Jorjani Biomed J 2024; 12 (2) :10-13
URL: http://goums.ac.ir/jorjanijournal/article-1-1044-en.html
URL: http://goums.ac.ir/jorjanijournal/article-1-1044-en.html
1- Department of Microbiology, Gorgan Branch, Islamic Azad University, Gorgan, Iran
2- Department of Microbiology, Gorgan Branch, Islamic Azad University, Gorgan, Iran ,lili_kia@yahoo.com
3- Department of Research and Technology, Golestan Univeristy of Medical Sciences, Gorgan, Iran
4- Department of Biophysics, Faculty of Biological Sciences, Gorgan Branch, Islamic Azad University, Gorgan, Iran
2- Department of Microbiology, Gorgan Branch, Islamic Azad University, Gorgan, Iran ,
3- Department of Research and Technology, Golestan Univeristy of Medical Sciences, Gorgan, Iran
4- Department of Biophysics, Faculty of Biological Sciences, Gorgan Branch, Islamic Azad University, Gorgan, Iran
Abstract: (543 Views)
Background: Cefiderocol is a siderophore cephalosporin with unique cell-penetrating abilities against multidrug-resistant (MDR) Gram-negative bacteria, especially carbapenem-resistant strains. This study aimed to evaluate the prevalence and susceptibility profiles of Cefiderocol on carbapenem-resistant uropathogenic Escherichia coli and Klebsiella pneumoniae isolates among hospitalized patients.
Methods: One hundred twenty-nine patients more than 72 h admitted to hospitals participated from Feb. 2021 to Dec. 2022. Urine samples were examined to identify uropathogenic K. pneumoniae and E. coli isolates based on microscopic morphology, cultural and biochemical methods. The carbapenemase production in the isolates was evaluated using modified Hodge tests and PCR. The MIC of Cefiderocol against carbapenemase-producing isolates was evaluated according to CLSI-2021 guidelines.
Results: According to phenotypic and genotypic tests, among forty-two E. coli isolates (71.19%) were carbapenemase positive, 38 isolates had the blaOXA gene (90.47%), and among twenty-four K. pneumoniae isolates 96% contained the blaKPC gene. In MIC determination 55.24% of carbapenem-resistant E. coli isolates were inhibited with ≤0.5 μg/ml of Cefiderocol, while only two strains (8.33%) of K. pneumoniae isolates showed resistance to the Cefiderocol (MIC90=2 μg/ml).
Conclusion: The present results demonstrate that the emergence of carbapenem-resistant uropathogenic bacteria poses a critical health threat to society. Based on the results, Cefiderocol demonstrated efficacy against carbapenem-resistant clinical isolates at low concentrations.
Methods: One hundred twenty-nine patients more than 72 h admitted to hospitals participated from Feb. 2021 to Dec. 2022. Urine samples were examined to identify uropathogenic K. pneumoniae and E. coli isolates based on microscopic morphology, cultural and biochemical methods. The carbapenemase production in the isolates was evaluated using modified Hodge tests and PCR. The MIC of Cefiderocol against carbapenemase-producing isolates was evaluated according to CLSI-2021 guidelines.
Results: According to phenotypic and genotypic tests, among forty-two E. coli isolates (71.19%) were carbapenemase positive, 38 isolates had the blaOXA gene (90.47%), and among twenty-four K. pneumoniae isolates 96% contained the blaKPC gene. In MIC determination 55.24% of carbapenem-resistant E. coli isolates were inhibited with ≤0.5 μg/ml of Cefiderocol, while only two strains (8.33%) of K. pneumoniae isolates showed resistance to the Cefiderocol (MIC90=2 μg/ml).
Conclusion: The present results demonstrate that the emergence of carbapenem-resistant uropathogenic bacteria poses a critical health threat to society. Based on the results, Cefiderocol demonstrated efficacy against carbapenem-resistant clinical isolates at low concentrations.
Type of Article: Original article |
Subject:
Health
Received: 2024/04/13 | Accepted: 2024/06/26 | Published: 2024/12/29
Received: 2024/04/13 | Accepted: 2024/06/26 | Published: 2024/12/29
References
1. Walas N, Slown S, Amato HK, Lloyd T, Bender M, Varghese V, et al. The role of plasmids in carbapenem resistant E. coli in Alameda County, California. BMC Microbiol. 2023;23(1):147. [View at Publisher] [DOI] [PMID] [Google Scholar]
2. Hosseinpour I, Fozouni L, Khademi M, Movaghari M, Akhoondi MM. The Impact of Gold Nanoparticle Susceptibility on Drug Resistance Phenotypes in Uropathogenic Escherichia coli. JoMMID. 2023;11(3):155-61. [View at Publisher] [DOI] [Google Scholar]
3. Mardani S, Fozouni L , Najafpour Gh . Zinc Oxide Nanoparticles: A Promising Solution for Controlling the Growth of Gentamicin-Resistant Uropathogenic Escherichia coli. IEM. 2022;8(2):99-106. [View at Publisher] [DOI] [Google Scholar]
4. Shahandeh Z, Sadighian F, Kalantrai N. Prevalence Escherichia coli, Klebsiella and Enterobacter Species and AmpC-producing Enterobacteriaceae in Clinical Specimens of Hospitals Affiliated to Babol University of Medical Sciences, Iran using Phenotypic and Molecular Methods. Iran J Med Microbiol. 2022;16(3):212-20. [View at Publisher] [DOI] [Google Scholar]
5. Huang E, yang xu, Leighton E, Li X. Carbapenem resistance in the food supply chain. J Food Prot. 2023;86(7):100108. [View at Publisher] [DOI] [PMID] [Google Scholar]
6. Sawa T, Kooguch K, Moriyama K. Molecular diversity of extended-spectrum β-lactamases and carbapenemases, and antimicrobial resistance. J Intensive Care. 2020;8:13. [View at Publisher] [DOI] [PMID] [Google Scholar]
7. Hsueh SC, Chao CM, Wang CY, Lai CC, Chen CH. Clinical efficacy and safety of cefiderocol in the treatment of acute bacterial infections: A systematic review and meta-analysis of randomised controlled trials. J Glob Antimicrob Resist. 2021;24:376-82. [View at Publisher] [DOI] [PMID] [Google Scholar]
8. Lee YR, Yeo S. Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-Resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety. Clin Drug Investig. 2020;40(10):901-13. [View at Publisher] [DOI] [PMID] [Google Scholar]
9. Sato T, Yamawaki K. Cefiderocol: Discovery, Chemistry, and In Vivo Profiles of a Novel Siderophore Cephalosporin. Clin Infect Dis. 2019;69(Suppl 7):S538-43. [View at Publisher] [DOI] [PMID] [Google Scholar]
10. Wu JY, Srinivas P, Pogue JM. Cefiderocol: A Novel Agent for the Management of Multidrug-Resistant Gram-Negative Organisms. Infect Dis Ther. 2020;9(1):17-40. [View at Publisher] [DOI] [PMID] [Google Scholar]
11. Ghotaslou R, Sadeghi MR, Akhi MT, Hasani A, Asgharzadeh M. Prevalence and Antimicrobial Susceptibility Patterns of ESBL, AmpC and Carbapenemase-producing Enterobactericeae Isolated from Hospitalized Patients in Azerbaijan, Iran. Iran J Pharm Res. 2018;17(Suppl):79-88. [View at Publisher] [PMID] [Google Scholar]
12. CLSI Publishes M100-Performance standards for antimicrobial susceptibility testing: 31st ed. USA:Clinical and Laboratory Standards Institute;2021. [View at Publisher]
13. Fazeli H, Norouzi-Barough M, Ahadi AM, Shokri D, Solgi H. Detection of New Delhi Metallo-Beta-Lactamase-1 (NDM-1) in carbapenem- resistant Klebsiella pneumoniae isolated from a university hospital in Iran. Hippokratia. 2015;19(3):205-09. [View at Publisher] [PMID] [Google Scholar]
14. Zhang LP, Xue WC, Meng DY. First report of New Delhi metallo-β-lactamase 5 (NDM-5)-producing Escherichia coli from blood cultures of three leukemia patients. Int J Infect Dis. 2016;42:45-6. [View at Publisher] [DOI] [PMID] [Google Scholar]
15. Ripabelli G, Sammarco ML, Scutellà M, Felice V, Tamburro M. Carbapenem-Resistant KPC- and TEM-Producing Escherichia coli ST131 Isolated from a Hospitalized Patient with Urinary Tract Infection: First Isolation in Molise Region, Central Italy, July 2018. Microb Drug Resist . 2020;26(1):38-45. [View at Publisher] [DOI] [PMID] [Google Scholar]
16. Murugan MS, Sinha DK, Vinodh Kumar OR, Yadav AK, Pruthvishree BS, Vadhana P, et al. Epidemiology of carbapenem-resistant Escherichia coli and first report of blaVIM carbapenemases gene in calves from India. Epidemiol Infect. 2019;147:e159. [View at Publisher] [DOI] [PMID] [Google Scholar]
17. Gurung S, Kafle S, Dhungel B, Adhikari N, Shrestha UT, Adhikari B, et al. Detection of OXA-48 Gene in Carbapenem-Resistant Escherichia coli and Klebsiella pneumoniae from Urine Samples. Infect Drug Resist. 2020;13:2311-21. [View at Publisher] [DOI] [PMID] [Google Scholar]
18. Moemen D, Masallat DT. Prevalence and characterization of carbapenem-resistant Klebsiella pneumoniae isolated from intensive care units of Mansoura University hospitals. Egypt J Basic Appl Sci .2017;4(1):37-41. [View at Publisher] [DOI] [Google Scholar]
19. Padovani M, Bertelli A, Corbellini S, Piccinelli G, Gurrieri F, De Francesco MA. In Vitro Activity of Cefiderocol on Multiresistant Bacterial Strains and Genomic Analysis of Two Cefiderocol Resistant Strains. Antibiotics (Basel). 2023;12(4):785. [View at Publisher] [DOI] [PMID] [Google Scholar]
20. Falagas M, Skalidis T, Vardakas K, Legakis N, Tsiplakou S, Papaioannou V, et al. Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals. J Antimicrob Chemother. 2017;72(6):1704-8. [View at Publisher] [DOI] [PMID] [Google Scholar]
21. Alzayer M, Alghoribi MF, Alalwan B, Alreheli A, Aljohani S, Bosaeed M, et al. In vitro activity of cefiderocol against clinically important carbapenem non-susceptible Gram-negative bacteria from Saudi Arabia. J Glob Antimicrob Resist. 2023:32:176-80. [View at Publisher] [DOI] [PMID] [Google Scholar]
22. Wang Y, Li Y, Zhao J, Guan J, Ni W, Gao Z. Susceptibility of cefiderocol and other antibiotics against carbapenem-resistant, Gram-negative bacteria. Ann Transl Med. 2022;10(5):261. [View at Publisher] [DOI] [PMID] [Google Scholar]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
